Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review)

Zhang, Weijia; Zhu, Min; Xiang, Ying; Sun, Yujiao; Li, Shuang; Cai, Jun; Zeng, Hai

doi:10.3892/or.2024.8724

Cited by 4 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Asia, the incidence of esophageal squamous cell carcinoma (ESCC) remains high, with over 90% of patients being pathologically classified as having this type of carcinoma ( 2 , 3 ). However, due to the lack of distinct early signs, many individuals are typically diagnosed when the disease is advanced, significantly impacting long-term survival prospects ( 4 , 5 ). These statistics underscore the significant threat that esophageal cancer poses to human health.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis

Wang,

Dong,

Liu

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Esophageal cancer is often overlooked in its early stages, with approximately 70% of patients being diagnosed at a locally advanced or late stage. Surgical treatment and chemotherapy are the mainstays of esophageal cancer management. However, for locally advanced esophageal cancer, both surgery alone and chemotherapy alone have high rates of recurrence and metastasis. The objective of the research was to investigate the security and therapeutic efficacy of neoadjuvant immunochemotherapy (NICT) in the treatment of resectable, locally advanced esophageal squamous cell carcinoma (ESCC). Methods We conducted a literature search on PubMed, Embase, Cochrane, Web of Science, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), China Biomedical Literature Database, and Wanfang for studies published before November 2023 that investigated on the clinical effectiveness and safety of neoadjuvant immunotherapy in resectable ESCC. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used for assessment, and Stata 17.0 was utilized for meta-analysis and sensitivity analysis. Results A total of 13 retrospective cohort studies involving 1,276 patients were included in this analysis. The NICT group showed a higher pathological complete response (pCR) rate [odds ratio (OR) =5.72; 95% confidence interval (CI), 3.40–9.63]. The major pathologic response (MPR) rate, objective response rate (ORR), R0 resection rate, and 1-year overall survival (OS) in the NICT group were better than those in the neoadjuvant chemotherapy (NCT) group (OR =3.70, 95% CI: 2.32–5.91; OR =2.22, 95% CI: 1.44–3.40; OR =2.63, 95% CI: 1.58–4.38; OR =10.08, 95% CI: 4.32–23.56). However, the NICT group also showed a drawback in terms of adverse reactions and postoperative complications. The incidence of rash (OR =4.69, 95% CI: 1.42–15.49) and pleural effusion (OR =3.99, 95% CI: 1.75–9.07) was significantly higher in the NCT group compared to the NICT group. The subgroup analysis indicates that the use of camrelizumab is associated with an increased incidence of rash. Additionally, performing a left thoracic esophagectomy and esophagogastric thoracic procedure significantly improved the R0 resection rate. Conclusions Neoadjuvant immunotherapy has shown promising efficacy in patients with locally advanced ESCC; however, it is linked to a higher occurrence of adverse events. Therefore, its use in clinical practice should be carefully considered.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis

Wang,

Dong,

Liu

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…In the advanced stages of esophageal cancer, particularly for patients with metastasis and recurrence, conventional chemotherapy is the only treatment option with limited efficacy [ 3 ]. Treating advanced esophageal cancer presents a myriad of challenges, stemming from the limitations of current treatment options, treatment toxicity, the development of chemoresistance, and the intricate nature of tumor biology [ 4 ]. The mechanisms underlying chemoresistance in esophageal cancer include the dysregulation of drug metabolism, impairment of apoptosis pathways, the presence of cancer stem cells, interactions with tumor-associated stromal cells, alterations in energy metabolism, and modifications to the tumor microenvironment [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation

Kai,

Kang,

Jiang

et al. 2024

Heliyon

View full text Add to dashboard Cite

Etomidate suppresses proliferation, migration, invasion, and glycolysis in esophageal cancer cells via PI3K/AKT pathway inhibition

Zhang,

Li,

Wang

2024

Cytotechnology

View full text Add to dashboard Cite

Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review)

Cited by 4 publications

References 84 publications

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: a systematic review and meta-analysis

Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation

Etomidate suppresses proliferation, migration, invasion, and glycolysis in esophageal cancer cells via PI3K/AKT pathway inhibition

Contact Info

Product

Resources

About